TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Patients With Ventricular Ectopy or VT During Exercise Treadmill Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Response Rate at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Clinical Phenotype Presenting Immune/Inflammatory Pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute risk of tooth sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CMAI scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of life scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of body fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebral intracranial aneurysms identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with completely closed ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erection Hardness Score (EHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF free survival rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forces generated during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Convergent Validity of the QoR-15
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Construct Validity of the QoR-15
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Discriminant Validity of the QoR-15
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Count of MRIs Successfully Modelled for Oxygen Correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reactive stepping ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bile composition differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Modification in surgical strategy
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Postprandial Glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Saphenous Vein Graft Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: surgical and non-surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Estimated iodine intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: combined incidence of late miscarriages and preterm births
Endpoint domain: Mortality/survival
Primary endpoint: Z-scores obtained using quantitative ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for AZD0284
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for AZD0284
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) for AZD0284
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Activated Clotting Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of VTE after OLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in clinical symptoms of ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in mitochondria number in skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Respiratory muscle performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Endoscopic Remission at Week 12/16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Remission at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of pregnancy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence rate of infant outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Penn Alcohol Craving Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood pressure after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in NRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 25 (OH)D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Herceptin-based therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: norbuprenorphine_Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: norbuprenorphine_AUCt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: norbuprenorphine_AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Arm volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of treatment for neonatal abstinence syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric strength of Biceps brachii muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hand grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of overall treatment adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Measurement of neural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in adherence to ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of ART
Endpoint domain: Adverse events/effects
Primary endpoint: safety of ART
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cold Symptoms (WURSS domain 2 score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of allele variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average monthly duration of epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hepatic disease progression events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Negative Biopsy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success/failure rate related to methadone switch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin sensitivity from hyperinsulinemic euglycemic clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Achieving 3 Million CD34 Cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Communicative Activity Log questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Boston Diagnostic Aphasia Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall survival rate in years
Endpoint domain: Mortality/survival
Primary endpoint: Free survival rate in years
Endpoint domain: Mortality/survival
Primary endpoint: IL-6 levels as a marker of treatment effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital Sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chest and Heart Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS) score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: International Knee Documentation Committee Subjective Knee Evaluation score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Zinreich CT Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging of corneal abrasions and infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal temperature cooling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin heat exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in expiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement of peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean absolute relative difference (MARD) % (accuracy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year regional recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Volumetric flow of cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinically Relevant Abnormalities for Clinical Laboratory Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Tolerability by the Investigator
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in OCD symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CD4+ T-cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health-Promotion Lifestyle Profile-Short
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective improvement of tinnitus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dollars spent on Fruits and Vegetables
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quantity of Fruits and Vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Degree of synovial senescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatosensory Evoked Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of new infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Retained at Follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reflectance spectrum of haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Psoriasis Area Severity Index (PASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroblast Growth Factor 23 (FGF23)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Musculoskeletal Symptom Sub-scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Hand Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes from baseline pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in quality of life on the scale IPSS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Evaluation of indicators of urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Evaluation of the inter-relapse period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of the decline in the log parasitemia-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in patient quality of life (QoL) using the EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in patient quality of life (QoL) using the FACT-P
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in patient quality of life (QoL) using the FACIT Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Evolution of Amyotrophic Lateral Sclerosis Functional Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Resolution of Shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Oral Mucosal Injury Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Syndrome Responder Status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite Pain Responder Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VZV gpELISA Antibody Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants recruited and retained to study completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pulmonary absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: visual assessment of raised [18F] brain uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average/Cumulative Opioid Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired cerebral compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recovery of Level of Consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Donor site pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BRG1 and BRM expression in rhabdoid tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic success (cured)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28 days in hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients completing treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lung function (FEV1) as percentage predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Daily Energy Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complications of safety outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Size reduction of Uterine Fibroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: % adherent subjects with applications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: % adherent subjects with nail preparation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: % Subjects satisfied to very satisfied with each study treatment at week 7
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dysfunctional voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence of Urinary Tract Infection (UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Urinary levels of renal biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of 99mTc-dimercaptosuccinic acid (DMSA) scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS) Pain sub-scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Trammpolin® meniscus prosthesis device related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Peak concentration (Cmax) of isoniazid, rifampin and pyrazinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time-concentration curve from 0-8 hours (AUC0-8h) of isoniazid, rifampin and pyrazinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antimullerian hormone values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Antral follicle count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Pulmonary Vascular Resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stent occlusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Presence of BioGlue on aortic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Same-day diagnosis and treatment of CT/NG
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Same-day diagnosis of HIV infection
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Identification of molecular subgroups sensitive or resistant to neoadjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in vascular reactivity measured by flow-mediated dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in platelet function measured by agonist-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Weekly Mean Average Daily Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of CDX2 mRNA Levels in Esophageal Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of CDX2 mRNA Levels in Esophageal Squamous Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation Status of NF-kB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neurostatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in HDRS-21 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence or absence of mucosal or systemic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: one-week point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities Arthritis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Duration of Voicing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Voice Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients showing 30% improvement in the JIA core set
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of CYP2D6 Genotypic Poor Metabolizers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate Post-injection Pain Severity by Subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate Post-injection Pain Severity by Investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet transfusions above threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in respiratory Visual analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Angle of thoracic kyphosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speech-to-noise ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptation Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fugl-Meyer Assessment Upper Limb Portion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calgary Depression rating Scale for Schizophrenia (CDSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adverse Neonatal Events
Endpoint domain: Adverse events/effects
Primary endpoint: Receipt of the first dose of HPV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety limit of 50 Hz srTMS
Endpoint domain: Adverse events/effects